Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Description

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Conditions

Lymphoma, B-Cell, Lymphoma, Large-cell Lymphoma, Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Condition
Lymphoma, B-Cell
Intervention / Treatment

-

Contacts and Locations

New York

Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York, United States, 10065

New York

NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York, New York, United States, 10065

New York

Weill Cornell Medical College (Data analysis only), New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Currently a hemotologic oncologist providing care to patients with DLBCL
  • * Per medical record, is being treated by a hematologic oncologist participating in this study
  • * Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
  • * Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or autologous stem cell transplant (ASCT)
  • * Self-identify as Black and/or White
  • * Per medical record, 18 years of age or older
  • * Per self-report, fluent in English\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
  • 1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
  • 2. What is your preferred language for healthcare? (must respond English)
  • * Per self-report, planning to leave the cancer center in the next 12 months
  • * Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
  • * Per research staff judgment and/or self-report, too ill or weak to complete study procedures
  • * Per medical record or self-report, receiving hospice care at the time of enrollment

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Kelly McConnell, PhD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2028-07-03